Current Value
$1.871 Year Return
Current Value
$1.871 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
NUKZ | 33.11% | $187.48M | 0.85% |
FFTY | 27.75% | $63.06M | 0.8% |
URA | 27.49% | $2.65B | 0.69% |
IZRL | 27.46% | $94.93M | 0.49% |
ARTY | 27.00% | $775.69M | 0.47% |
ITEQ | 26.93% | $86.87M | 0.75% |
SKYY | 25.62% | $3.12B | 0.6% |
IWC | 25.26% | $797.08M | 0.6% |
SIXG | 25.23% | $528.16M | 0.3% |
ARKF | 25.14% | $884.68M | 0.75% |
XSW | 25.13% | $460.40M | 0.35% |
ISRA | 25.13% | $91.54M | 0.59% |
PRNT | 24.77% | $73.21M | 0.66% |
PSP | 24.61% | $251.86M | 1.79% |
WCLD | 24.60% | $400.75M | 0.45% |
ARKX | 24.33% | $258.10M | 0.75% |
BUZZ | 24.19% | $48.67M | 0.76% |
ARKW | 24.11% | $1.49B | 0.82% |
KOMP | 23.99% | $1.95B | 0.2% |
FPX | 23.87% | $736.68M | 0.59% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -17.93% | $23.50B | +25.53% | 1.05% |
PEP | -17.58% | $204.52B | -12.12% | 3.52% |
CNC | -17.11% | $30.13B | -16.85% | 0.00% |
CL | -16.43% | $75.88B | +6.19% | 2.07% |
KO | -16.07% | $306.97B | +19.22% | 2.66% |
STNG | -15.97% | $1.87B | -48.89% | 4.57% |
AWK | -15.96% | $28.51B | +22.92% | 1.99% |
AEP | -15.92% | $57.54B | +27.77% | 3.31% |
LHX | -15.07% | $39.78B | +3.74% | 2.23% |
T | -14.86% | $201.99B | +59.80% | 3.85% |
ELV | -14.21% | $97.61B | -15.15% | 1.51% |
MUR | -14.06% | $4.26B | -39.61% | 4.75% |
LMT | -13.95% | $106.60B | +1.11% | 2.84% |
INGR | -13.93% | $8.69B | +18.28% | 2.34% |
ES | -13.84% | $22.99B | +7.19% | 4.61% |
MOH | -13.83% | $17.97B | -13.21% | 0.00% |
GIS | -13.71% | $32.41B | -14.20% | 3.90% |
MKC | -13.55% | $21.80B | +6.61% | 2.08% |
EOG | -13.39% | $71.99B | -2.85% | 3.06% |
CI | -13.29% | $89.99B | -8.07% | 1.68% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DOCS | 0.01% | $10.87B | +125.49% | 0.00% |
ENPH | -0.02% | $8.28B | -47.28% | 0.00% |
BCRX | -0.02% | $1.55B | +57.08% | 0.00% |
CB | 0.02% | $120.74B | +18.35% | 1.19% |
OHI | 0.02% | $10.68B | +21.25% | 6.79% |
KOF | -0.03% | $4.99B | +1.35% | 4.18% |
MSDL | 0.03% | $1.79B | -4.01% | 9.98% |
SPGI | -0.05% | $161.31B | +20.52% | 0.74% |
LIND | -0.05% | $522.39M | +14.47% | 0.00% |
INVH | 0.05% | $21.22B | -0.32% | 3.31% |
EQX | -0.05% | $3.01B | +1.69% | 0.00% |
MNSO | 0.05% | $5.95B | -9.15% | 1.56% |
LLY | -0.06% | $775.66B | +5.44% | 0.68% |
MGEE | -0.07% | $3.40B | +18.68% | 1.91% |
TIMB | -0.07% | $7.73B | -10.84% | 3.11% |
FIZZ | 0.08% | $3.90B | -9.84% | 0.00% |
AVD | -0.08% | $122.92M | -66.48% | 0.75% |
BHC | 0.09% | $2.25B | -39.14% | 0.00% |
BTCT | 0.09% | $20.15M | +14.57% | 0.00% |
BMRN | -0.10% | $13.03B | -21.27% | 0.00% |
Yahoo
Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea’s experimental drug, ATRN-119, over a 24-hour daily cycle New regimen potentially optimizes clinical outcomes and strengthens the clinical path forward ATRN-119 is the first macrocyclic ATR inhibitor to enter clinical trials DOYLESTOWN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision oncology
Yahoo
After losing some value lately, a hammer chart pattern has been formed for Aprea Therapeutics (APRE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Yahoo
Aprea Therapeutics ( NASDAQ:APRE ) Third Quarter 2024 Results Key Financial Results Net loss: US$3.78m (loss widened by...
Yahoo
Aprea Therapeutics (APRE) delivered earnings and revenue surprises of 14.67% and 21.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected toxicities Philippe Pultar, MD engaged as senior medical advisor to support the development and advancement of APR-1051 $26.2 million in cash and cash equivalents as of September 30, 2024 with cash runway for at least twelve months DOYLESTOWN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a cl
Yahoo
Pacira (PCRX) delivered earnings and revenue surprises of 9.72% and 0.91%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XLV | 0.02% | $37.76B | 0.09% |
LMBS | 0.07% | $4.90B | 0.64% |
IBHE | -0.07% | $590.52M | 0.35% |
BUXX | -0.09% | $234.79M | 0.25% |
FLDR | 0.18% | $775.30M | 0.15% |
YEAR | 0.20% | $1.28B | 0.25% |
UTEN | -0.28% | $187.53M | 0.15% |
KCCA | 0.29% | $108.04M | 0.87% |
IEF | 0.30% | $35.09B | 0.15% |
ULST | 0.30% | $585.14M | 0.2% |
HTRB | -0.31% | $2.00B | 0.29% |
IBMP | -0.32% | $513.49M | 0.18% |
XHLF | -0.35% | $1.06B | 0.03% |
IBTO | 0.37% | $334.00M | 0.07% |
OWNS | -0.45% | $134.08M | 0.3% |
NOBL | 0.47% | $11.75B | 0.35% |
IBTG | -0.50% | $1.82B | 0.07% |
IBMR | 0.53% | $222.54M | 0.18% |
GOVI | -0.56% | $1.07B | 0.15% |
XONE | -0.58% | $631.21M | 0.03% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
OKLO | 31.33% | $3.16B | +76.38% | 0.00% |
NNOX | 30.57% | $287.24M | -54.79% | 0.00% |
CLFD | 29.15% | $417.73M | -0.37% | 0.00% |
FLR | 27.56% | $6.25B | -12.09% | 0.00% |
LTRN | 27.09% | $36.88M | -60.42% | 0.00% |
NNDM | 26.61% | $339.82M | -43.43% | 0.00% |
UEC | 26.61% | $2.02B | -38.67% | 0.00% |
CMC | 26.34% | $5.32B | -18.88% | 1.73% |
CCJ | 25.90% | $18.49B | -14.82% | 0.28% |
PSTG | 25.82% | $15.00B | -14.05% | 0.00% |
OLO | 25.66% | $1.03B | +19.27% | 0.00% |
TLPH | 25.62% | $9.97M | -42.28% | 0.00% |
OR | 25.58% | $3.92B | +27.61% | 0.88% |
TPG | 25.57% | $5.31B | +10.19% | 4.04% |
JHG | 25.45% | $5.80B | +13.71% | 4.73% |
FOLD | 25.21% | $2.45B | -29.73% | 0.00% |
KRRO | 24.96% | $162.80M | -77.76% | 0.00% |
LAC | 24.93% | $603.57M | -61.07% | 0.00% |
IMAB | 24.91% | $59.95M | -57.47% | 0.00% |
UUUU | 24.89% | $792.61M | -45.36% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -19.09% | $416.76M | 1.43% |
DBE | -16.34% | $55.52M | 0.77% |
CCOR | -15.60% | $64.12M | 1.18% |
DBO | -14.23% | $202.41M | 0.77% |
COMT | -13.49% | $684.20M | 0.48% |
USDU | -13.32% | $206.96M | 0.5% |
IYK | -13.14% | $1.53B | 0.4% |
USL | -13.12% | $47.77M | 0.85% |
TAIL | -12.96% | $87.65M | 0.59% |
BNO | -12.82% | $99.25M | 1% |
VIXY | -12.75% | $195.31M | 0.85% |
OILK | -12.65% | $67.85M | 0.69% |
GSG | -12.55% | $1.05B | 0.75% |
USO | -12.54% | $972.70M | 0.6% |
USCI | -12.31% | $240.82M | 1.07% |
PDBC | -12.29% | $4.89B | 0.59% |
UGA | -12.25% | $87.23M | 0.97% |
FTXG | -11.14% | $26.06M | 0.6% |
DBC | -11.03% | $1.36B | 0.87% |
UUP | -10.42% | $325.79M | 0.77% |